FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2012451003> ?p ?o ?g. }

• W2012451003 endingPage "32" @default.
• W2012451003 startingPage "22" @default.
• W2012451003 abstract "Ovarian cancer, one of the poor-prognosis gynecological malignancies, is often associated with extensive peritoneal carcinomatosis when initially treated. The mechanism of the formation of peritoneal carcinomatosis from ovarian cancer is still unknown. It has been reported that overexpression of cancer-related growth factors and/or receptors may worsen the prognosis of diseases. In the previous paper, we had established the human ovarian serous adenocarcinoma cell lines from those with no potentiality of peritoneal dissemination (FOC-3) to high potentiality (MFOC-3), however, the mechanism of its phenotypical change remains unknown. In this paper, we compared these two cell lines for growth potential and the expression of growth factor heregulin (HRG)-1α and HER-2, HER-3, and HER-4 receptors. In addition, the effect of anti-receptor antibodies on cell growth was investigated. RT-PCR and Western blot analysis found the promotion of the expression of HRG precursor and HRG-1α in MFOC-3. Examination of the number of growing cells over time revealed a statistically significant increase in the number of cells in MFOC-3 compared with FOC-3. In a study using the addition of exogenous HRG-1α, no changes were observed in FOC-3 while statistically significant cell growth was noted in MFOC-3. In a growth inhibition study, statistically significant cell growth inhibition was achieved with the addition of anti-HER2 receptor antibody. Taken together, the results of this study suggested that HRG may play an important role in the increased growth potential of peritoneal dissemination of ovarian cancer. In particular, HER-2 receptors that can act as a starting point to trigger intracellular signaling pathways are strongly involved in the progression of cancer. Therefore, molecular target drug therapies blocking the HER-2 receptor are promising candidates for ovarian cancer treatment in the future." @default.
• W2012451003 created "2016-06-24" @default.
• W2012451003 creator A5003235635 @default.
• W2012451003 creator A5065805983 @default.
• W2012451003 creator A5085436309 @default.
• W2012451003 creator A5088218136 @default.
• W2012451003 date "2012-01-01" @default.
• W2012451003 modified "2023-09-23" @default.
• W2012451003 title "ASSOCIATION BETWEEN GROWTH FACTOR HEREGULIN -1^|^alpha; AND RECEPTORS IN GROWTH OF OVARIAN CANCER CELL LINE WITH HIGH POTENTIALITY OF PERITONEAL DISSEMINATION" @default.
• W2012451003 cites W1501252326 @default.
• W2012451003 cites W1513348879 @default.
• W2012451003 cites W1564868464 @default.
• W2012451003 cites W1849285658 @default.
• W2012451003 cites W1964321121 @default.
• W2012451003 cites W1973188134 @default.
• W2012451003 cites W1990654868 @default.
• W2012451003 cites W1996571855 @default.
• W2012451003 cites W1997136340 @default.
• W2012451003 cites W2001124278 @default.
• W2012451003 cites W2006621710 @default.
• W2012451003 cites W2011945440 @default.
• W2012451003 cites W2014032634 @default.
• W2012451003 cites W2017397076 @default.
• W2012451003 cites W2043471865 @default.
• W2012451003 cites W2050448723 @default.
• W2012451003 cites W2052365599 @default.
• W2012451003 cites W2056579307 @default.
• W2012451003 cites W2080844302 @default.
• W2012451003 cites W2095156669 @default.
• W2012451003 cites W2105847083 @default.
• W2012451003 cites W2108410343 @default.
• W2012451003 cites W2116323570 @default.
• W2012451003 cites W2121452569 @default.
• W2012451003 cites W2151127067 @default.
• W2012451003 cites W2154027407 @default.
• W2012451003 cites W2156157818 @default.
• W2012451003 cites W2160425081 @default.
• W2012451003 cites W2167132924 @default.
• W2012451003 cites W2332928500 @default.
• W2012451003 cites W2344444710 @default.
• W2012451003 cites W2415747809 @default.
• W2012451003 cites W2473628628 @default.
• W2012451003 cites W2015548499 @default.
• W2012451003 cites W2165904563 @default.
• W2012451003 doi "https://doi.org/10.5387/fms.58.22" @default.
• W2012451003 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22790889" @default.
• W2012451003 hasPublicationYear "2012" @default.
• W2012451003 type Work @default.
• W2012451003 sameAs 2012451003 @default.
• W2012451003 citedByCount "1" @default.
• W2012451003 countsByYear W20124510032019 @default.
• W2012451003 crossrefType "journal-article" @default.
• W2012451003 hasAuthorship W2012451003A5003235635 @default.
• W2012451003 hasAuthorship W2012451003A5065805983 @default.
• W2012451003 hasAuthorship W2012451003A5085436309 @default.
• W2012451003 hasAuthorship W2012451003A5088218136 @default.
• W2012451003 hasBestOaLocation W20124510031 @default.
• W2012451003 hasConcept C121608353 @default.
• W2012451003 hasConcept C126322002 @default.
• W2012451003 hasConcept C130287650 @default.
• W2012451003 hasConcept C150173356 @default.
• W2012451003 hasConcept C170493617 @default.
• W2012451003 hasConcept C185323287 @default.
• W2012451003 hasConcept C26375932 @default.
• W2012451003 hasConcept C2775960820 @default.
• W2012451003 hasConcept C2779707156 @default.
• W2012451003 hasConcept C2780427987 @default.
• W2012451003 hasConcept C502942594 @default.
• W2012451003 hasConcept C54355233 @default.
• W2012451003 hasConcept C62112901 @default.
• W2012451003 hasConcept C71924100 @default.
• W2012451003 hasConcept C81885089 @default.
• W2012451003 hasConcept C86803240 @default.
• W2012451003 hasConceptScore W2012451003C121608353 @default.
• W2012451003 hasConceptScore W2012451003C126322002 @default.
• W2012451003 hasConceptScore W2012451003C130287650 @default.
• W2012451003 hasConceptScore W2012451003C150173356 @default.
• W2012451003 hasConceptScore W2012451003C170493617 @default.
• W2012451003 hasConceptScore W2012451003C185323287 @default.
• W2012451003 hasConceptScore W2012451003C26375932 @default.
• W2012451003 hasConceptScore W2012451003C2775960820 @default.
• W2012451003 hasConceptScore W2012451003C2779707156 @default.
• W2012451003 hasConceptScore W2012451003C2780427987 @default.
• W2012451003 hasConceptScore W2012451003C502942594 @default.
• W2012451003 hasConceptScore W2012451003C54355233 @default.
• W2012451003 hasConceptScore W2012451003C62112901 @default.
• W2012451003 hasConceptScore W2012451003C71924100 @default.
• W2012451003 hasConceptScore W2012451003C81885089 @default.
• W2012451003 hasConceptScore W2012451003C86803240 @default.
• W2012451003 hasIssue "1" @default.
• W2012451003 hasLocation W20124510031 @default.
• W2012451003 hasLocation W20124510032 @default.
• W2012451003 hasLocation W20124510033 @default.
• W2012451003 hasOpenAccess W2012451003 @default.
• W2012451003 hasPrimaryLocation W20124510031 @default.
• W2012451003 hasRelatedWork W1968490444 @default.
• W2012451003 hasRelatedWork W1985693888 @default.
• W2012451003 hasRelatedWork W2012451003 @default.

• next